Several possible toxicological and genetic tools for the extension of the detection window after GHB intake by Mehling, Lena-Maria et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Several possible toxicological and genetic tools for the extension of the detection
window after GHB intake
Mehling, Lena-Maria; Piper, Thomas ; Lott, Susanne; Wang, Xin; Dib, Josef; Pedersen,
Daniel Sejer; Heidbreder, Anna; Young, Peter; Madea, Burkhard; Johansen, Sys Stybe;
Courts, Cornelius; Thevis, Mario; Hess, Cornelius
Published in:
Toxichem Krimtech
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Mehling, L-M., Piper, T., Lott, S., Wang, X., Dib, J., Pedersen, D. S., ... Hess, C. (2017). Several possible
toxicological and genetic tools for the extension of the detection window after GHB intake. Toxichem Krimtech,
84(3), 184-190.
Download date: 10. Sep. 2020
 
 
Several possible toxicological and genetic tools  
for the extension of the detection window after GHB intake  
 
Lena-Maria Mehling1,*, Thomas Piper2, Susanne Lott1, Xin Wang6, Josef Dib2, Daniel 
Sejer Pedersen3, Anna Heidbreder5, Peter Young5, Annika Spottke7, Burkhard Madea1, 
Sys Stybe Johansen6, Cornelius Courts4, Mario Thevis2, Cornelius Hess1 
 
1Institute of Forensic Medicine, Bonn (Germany), *Lena-Maria.Mehling@ukbonn.de 
2Center for Preventive Doping Research, Institute of Biochemistry, German Sport University 
Cologne, Cologne (Germany) 
3Department of Drug Design and Pharmacology, Faculty of Health and Medical Science, 
University of Copenhagen, Copenhagen (Denmark)  
4Institute of Forensic Medicine, Kiel (Germany) 
5Department of Neurology, Division of Sleep Medicine and Neuromuscular Disorders, 
Münster (Germany) 
6Department of Forensic Medicine, University of Copenhagen (Denmark) 
7Department of Neurology, Bonn (Germany) 
 
 
 
Aims: Because of its short detection window, uncovering the intake of gamma-
hydroxybutyric acid (GHB) still constitutes a problem. Aim of the experiments was to 
develop and evaluate new tools for a possible extension of the detection window after the 
intake of GHB. Methods: Blood, plasma and urine samples (each n=49) of volunteers and of 
patients (n=3, patient 1 and 2 chronical intake, patient 3 single intake) therapeutically taking 
up to 4.5 g GHB (Xyrem®) per night were collected at different points in time after the intake 
up to 72 h. Additionally, hair samples of the patients were taken. Concentration profiles of 
GHB (high-performance liquid chromatography-tandem mass spectrometry), GHB-β-
glucuronide and GHB-4-sulfate (high-performance liquid chromatography-quadrupole time-
of-flight-mass spectrometry) in plasma and urine were recorded over time. Hair samples were 
analyzed by a validated LC-MS/MS method for GHB and GHB-β-glucuronide. Alterations in 
gene expression of ALDH5A1, AKR7A2, EREG and PEA15 in blood, genes of interest which 
code for enzymes involved in GHB metabolism, was investigated via quantitative PCR using 
an empirically derived normalization strategy. Furthermore, possible discrimination of 
endogenous from exogenous GHB in urine via isotope ratio MS was tested. Results and 
discussion: The parent compound could be quantified above the usual cut-offs for 4-6 hours 
both in blood and urine. No discrimination endogenous/exogenous by neither using the phase 
II metabolites of GHB nor using the expression of the genes of interest was possible. In the 
hair samples of patients GHB and its glucuronide could not be determined in concentrations 
higher than the control group. A discrimination endogenous/exogenous GHB was only 
possible using isotope ratio mass spectrometry, however carbon isotope ratios in urine did not 
differ longer than GHB was detectable above the cut-off limit. Conclusion: Therefore, these 
methods do not seem to be able to extend the detection window of exogenous GHB. 
 
 
1. Introduction 
 
Gamma-hydroxybutyric acid (GHB) is a central nervous system depressant which is 
generated endogenously originating from the neurotransmitter GABA (gamma-aminobutyric 
acid) via the enzymes GABA-transaminase and succinat-semialdehyde-reductase [1]. Apart 
from its natural occurrence, GHB is therapeutically taken for the treatment of narcolepsy [2] 
and its use emerged as a so-called knockout-drug for drug facilitated crimes (DFCs) [3]. 
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Uncovering DFCs related to GHB has been difficult, due to its very narrow detection window 
in plasma (<6 h) and urine (<12 h) depending on the ingested dose [4, 5]. Commonly used 
cutoff values in ante mortem samples are 4 mg/L for plasma and 6 mg/L for urine [6]. In 
2013, the GHB metabolite GHB-β-O-glucuronide (GHB-Gluc) in urine samples was 
described by Petersen et al. [7] and Hanisch et al. [8] described the sulfonated GHB (GHB-
Sulf) in urine samples in 2015. 
 
To date only few studies applying alternative methodologies to verify GHB exposure and to 
widen the window of detection are available. Saudan et al. [9] employed gas chromatography 
isotope ratio mass spectrometry (GC/C/IRMS) to determine the differences in carbon isotope 
composition between exogenous and endogenous GHB in blood samples of human subjects. 
Furthermore, hair analyses of human subjects after GHB intake were investigated by several 
research groups [10-12]. A new approach was conducted by Larson et al. [13] with the aim to 
identify a surrogate marker for GHB intake. They showed that the genes PEA-15 and EREG 
were significantly higher expressed in mice which received an intraperitoneal GHB injection.  
The aim of the present study was to find a new potential approach for the determination of an 
exogenous GHB intake via toxicological, biochemical or genetic investigations.  
 
 
2. Material and Methods 
 
2.1. Study design 
 
The study design was approved by the regional ethics committee of the University Hospital of 
Bonn according to the declaration of Helsinki (number: 370/13). The volunteers were 
informed about the risks of the study and gave their written informed consent. Biological 
specimens were collected from volunteers with (case group, n=3) and without (control group, 
n=49) GHB-intake.  
 
2.1.1. Case group 
 
Participants were patients suffering from narcolepsy (n=3). The first two volunteers took daily 
the pharmaceutical Xyrem® for more than five years. Test person 1 and 2 stopped taking the 
medication 3 days and 18 h before the experiment started, respectively. For the excretion 
study P1 and P2 took the pharmaceutical Xyrem® with a dose of 2.25 g (1.87 g GHB). 
Subsequently whole blood and urine samples were collected prior to and after 0.5, 1, 1.5, 2, 4, 
6, 8, 12, 24, 48 and 72 h and were stored at -20°C. Test person 3, diagnosed as narcolepsy, 
was drug free before participating in the trial. Whole blood in PAXgene tubes, plasma and 
urine samples of P3 were collected after a single dose administration of 2.42 g sodium 
oxybate solution (volume: 10 mL, 2 g GHB, Somsanit®) according to the protocol described 
above. Sample collection of P3 finished 24 h after GHB exposure.  
 
Hair samples were collected from the back of the head from each patient and stored at room 
temperature. The hair sample of P1 was 37 cm long and bleached; original hair colour was 
dark blond. P2 had 50 cm long, brown hair; the original hair colour was light brown. The 
distal 20-25 cm of the hair strand were dyed with brown hair colour and were not involved in 
the investigation. The hair of P3 was black and without hair treatment (hair length: 6 cm). 
 
2.1.2. Control group 
 
Blood in PAXgene tubes, plasma and urine samples were collected from volunteers (n=49) 
who had never taken GHB during their lives and stored at (-20°C and -80°C for RNA) until 
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analysis. Control group did not differ significantly from the three cases in age (p>0.05) and 
BMI (p>0.05) by assessing the Mann-Whitney-U-test.  
 
2.2. Materials and Methods 
 
GHB and its metabolites GHB-Gluc and GHB-Sulf were analysed and determined in plasma 
and urine samples via high-performance liquid chromatography-tandem mass spectrometry 
(LC/MS/MS) and high-performance liquid chromatography-quadrupole time-of-flight-mass 
spectrometry (LC-QTOF-MS). Method details have been published elsewhere [14, 15]. The 
approach to measure exogenous GHB in urine using isotope ratio mass spectrometry (IRMS) 
was also previously published [16]. Alterations in gene expression of the genes ALDH5A1, 
AKR7A2, EREG and PEA15 after GHB intake were analyzed by quantitative Realtime-PCR. 
ALDH5A1 and AKR7A2 were chosen, because they code for enzymes involved in GHB meta-
bolism. Former experiments showed that the expression of the genes EREG and PEA15 increa-
sed in mice when GHB was injected [13]. Therefore, EREG and PEA15 were also investiga-
ted. An empirically derived normalization strategy was established for this approach. Method 
details were described in Mehling et al. Int J Legal Med “Alterations in gene expression after 
gamma-hydroxybutyric acid intake - a pilot study” (accepted may 2017). 
 
 
3. Results and Discussion 
 
3.1. Toxicological Investigations 
3.1.1. Analysis in plasma and urine 
 
We investigated GHB and GHB-Gluc concentrations in plasma and urine samples of 49 cont-
rols and compared the results with plasma and urine samples of three patients taking GHB for 
the indication of narcolepsy [17]. 
 
For the three positive cases excretion patterns are shown in Figure 1. GHB plasma concentra-
tions of all patients decreased and fell below the commonly applied cutoff value 4 h after in-
gestion (Fig. 1, left). In urine, GHB concentrations were measured below the cutoff value of 
10 mg/L after 6 h in P1 and P3 as well as after 8 h in P2 (Fig. 1, right). Results were previ-
ously published [17]. 
 
Fig. 1. Gamma-hydroxybutyric 
acid (GHB) concentrations of 
the three test persons after in-
gestion of sodium oxybate plot-
ted against collected time in 
plasma (left) and urine (right). 
(▬) marks the commonly used 
cutoffs in plasma (<4 mg/L). 
P1 first (-♦-), P2 second (-■-), 
P3 third test person (-▲-). 
 
Results of GHB-Gluc in urine and plasma were already published elsewhere [17]. Briefly, in 
Figure 2 GHB-Gluc concentration-time profiles for plasma of the three test-persons (P1-3) are 
displayed. The underlying lines depict the range of determined endogenous plasma GHB-
Gluc concentrations in the control group. In general, GHB-Gluc concentrations showed no 
time-depended increase after GHB intake (Fig. 2). GHB-Gluc concentrations of the P2 and P3 
were in the same range as the control group. P1 showed higher GHB-Gluc concentrations in 
plasma, which were determined above the maximum of the 49 volunteers of the control 
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group. The GHB-Gluc concentration of P1 even before GHB administration was above the 
maximum level of the control group.  
  
Figure 3 (below) shows the GHB-Gluc concentrations of the 
case group (P1-3) compared to the ranges of endogenous 
GHB-Gluc concentrations without GHB-intake in urine 
samples. In addition, urinary GHB-Gluc concentrations nor-
malized by creatinine concentrations are also depicted (right 
side). For P1, GHB-Gluc concentrations were determined 
above the maximum concentration of the control group (5.09 
mg/L). The measured concentrations of P2 and P3 were al-
most within the endogenous concentration range in urine 
samples. Before GHB ingestion GHB-Gluc concentrations 
were determined to be 11.56, 3.12 and 1.34 mg/L for P1, P2 
and P3, respectively. After GHB intake GHB-Gluc concen-
trations increased in all test persons, but the determined ele-
vated levels were almost within the studied range of the 
control group without GHB exposure.  
 
Fig. 2. GHB-Gluc concentrations in plasma samples of the three test per-
sons compared to endogenous plasma concentrations of the control 
group. The blue area shows the endogenous concentrations between the 
first and third quartile (Q1= first quartile (▬); Q3= third quartile (▬)) of 
the control group. Below and above the blue area, lines for minimum 
(− −) and maximum (− · ·) of the endogenous plasma concentrations are 
drawn together with the median (▬); P1 first (-♦-), P2 second (-■-), P3 
third test person (-▲-). 
 
Maximum GHB-Gluc con-
centrations were determi-
ned after 6 h (P1, P3) and 8 
h (P2).  
 
 
Fig. 3. GHB-Gluc concentrations 
of the three test persons in urine 
compared to endogenous urine 
concentrations of the control 
group with (right) and without 
(left) normalization to creatinine. 
The blue area shows the endoge-
nous concentrations between the 
first and third quartile (Q1= first 
quartile (▬); Q3= third quartile 
(▬)) of the control group. Below 
and above the blue area lines for 
minimum (− −) and maximum 
(− · ·) of the endogenous plasma 
concentrations are drawn to-
gether with the median (▬); P1 
first test person (-♦-), P2 second 
test person (-■-), P3 third test 
person (-▲-). 
 
After normalization with creatinine concentrations the values for GHB-Gluc of P1 were above 
the third quartile, but largely below the maximum endogenous concentration of the control 
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group. Furthermore, an increase of GHB-Gluc values could also be observed in P1 and P3 
after normalization by creatinine concentrations in urine, contrary to P2, where no increase 
was observed. Due to drinking of relatively large volumes of water after GHB administration 
the urine samples of P2 at the time-points 2 and 4 h were highly diluted. Therefore, less GHB, 
GHB-Gluc and creatinine concentrations were found in these urine samples.  
 
The determined GHB-Gluc concentrations of the three test persons in plasma and urine 
showed no noteworthy results compared to the control group. Almost no time-depended 
increases of the GHB-Gluc concentrations exceeding the maximum level of the control group 
were determined in plasma and urine of P2 and P3 after GHB intake. Hitherto, the GHB-
metabolite GHB-Gluc seems not to be a suitable marker in plasma and urine to extend the 
detection window after GHB intake [17]. 
 
Results about the suitability of GHB-sulfate as a potential marker to uncover a GHB intake 
will soon be published. The article is still within publication process (Piper et al. submitted to 
Forensic Sci. Int. “Potential of GHB-4-sulfate to complement current approaches in GHB 
post administration detection”). 
 
3.1.2. Hair analysis 
 
The investigations on hair showed that a single GHB exposure might not be determined by 
hair analysis of GHB and GHB-Gluc (P3). The chronical intake of therapeutic sodium oxy-
bate was also not confirmed by hair analysis maybe due to hair treatments (P1 and P2). Re-
gardless of sampling time or pre-analysis treatment of the hair no increased concentrations of 
GHB and its glucuronide were detected. Therefore, GHB hair analysis should be assessed 
critically and determined negative results cannot exclude GHB exposures, because chronical 
therapeutic use could lead to endogenous GHB hair concentrations. Further information will 
soon be published. The article is still within publication process (Mehling et al. submitted to 
Forensic Sci Int “Determination of GHB and GHB-O-β-glucuronide in hair of three narco-
leptic patients - Comparison between single and chronic GHB exposure”). 
 
3.2. Biochemical investigations 
 
The previously published results showed that the determination of the isotope ratio of GHB 
after GHB intake enables to distinguish between endogenously produced and exogenous 
ingested GHB [16]. Firstly the Carbon isotope ratio (CIR) of Xyrem® was measured and 
correlated to the internationalen Standard Vienna Pee Dee Belemnite (VPDB): δ13CVPDB = 
-28.6±0.1 ‰ [16]. Afterwards the CIR δ13CVPDB were determined in the collected urine 
samples (Tab. 1).  
 
Tab. 1. Concentrations and CIR of GHB in urine samples, CIR = carbon isotope ratio. 
 
 
 
 
 The results show that the CIR values of 
 urinary GHB are significantly influen-
 ced after administration. Presumably 
 due to its fast metabolism, differences 
 in the isotope  composition of the ana-
 lyzed molecules could only be detected 
up to 4 hours after GHB intake. Therefore, the detection window of GHB intake could not be 
prolonged by using this technique.  
Time [h] Concentration [mg/L] CIR (GHB) 
0 1.69 -23.66 
2 254 -28.66 
4 66.9 -28.42 
6 4.25 -25.72 
8 1.56 -24.11 
12 1.55 -24.29 
22 0.83 not detected 
46 0.88 not detected 
70 0.91 not detected 
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3.3. Genetic Investigations 
 
We investigated the expression of ALDH5A1, AKR7A2, EREG and PEA-15 of P1, P2 and P3 
after GHB intake and compared the results with the gene expression levels of the control 
group. The genes of interest ALDH5A1, AKR7A2, EREG and PEA15 showed no alterations in 
gene expression compared to the values of the control group. Further information are shown 
in a recently published article in Int J LegMed (Mehling et al. Int J Legal Med “Alterations in 
gene expression after gamma-hydroxybutyric acid intake - a pilot study”, accepted may 
2017). 
 
 
4. Conclusions  
 
In this study interdisciplinary investigations were performed to find a potential biomarker or a 
new strategy for the identification of a GHB intake. In summary, no promising approach 
could reach this aim neither toxicological, biochemical nor genetic investigations. The 
metabolites GHB-Gluc and GHB-Sulf could not widen the detection window in plasma and 
urine samples. Furthermore, hair analysis could not provide an evidence for single or multiple 
GHB administrations in therapeutically dosages. Additionally, the isotope ratios of 
endogenously generated and industrially synthesized GHB could identify the origin of the 
excreted GHB in urine samples after ingestion, but this approach could not extend the 
detection window. Finally, no significant differences in expression of the genes ALDH5A1, 
AKR7A2, EREG and PEA15 between peripheral blood samples in case and control groups 
were observed. Further investigations should be conducted to find another approach to extend 
the detection window after GHB intake. 
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